MX2016003763A - Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. - Google Patents
Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.Info
- Publication number
- MX2016003763A MX2016003763A MX2016003763A MX2016003763A MX2016003763A MX 2016003763 A MX2016003763 A MX 2016003763A MX 2016003763 A MX2016003763 A MX 2016003763A MX 2016003763 A MX2016003763 A MX 2016003763A MX 2016003763 A MX2016003763 A MX 2016003763A
- Authority
- MX
- Mexico
- Prior art keywords
- multiple sclerosis
- laquinimod
- treatment
- combination therapy
- subject
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title abstract 4
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004577 laquinimod Drugs 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 206010071068 Clinically isolated syndrome Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361883698P | 2013-09-27 | 2013-09-27 | |
| PCT/US2014/057705 WO2015065628A2 (en) | 2013-09-27 | 2014-09-26 | Laquinimod combination therapy for treatment of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016003763A true MX2016003763A (es) | 2016-10-28 |
Family
ID=52740749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016003763A MX2016003763A (es) | 2013-09-27 | 2014-09-26 | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20150094332A1 (enExample) |
| EP (1) | EP3049075A4 (enExample) |
| JP (1) | JP2016533323A (enExample) |
| KR (1) | KR20160085757A (enExample) |
| CN (1) | CN105848653A (enExample) |
| AR (1) | AR097792A1 (enExample) |
| AU (1) | AU2014342917A1 (enExample) |
| BR (1) | BR112016006582A2 (enExample) |
| CA (1) | CA2925493A1 (enExample) |
| EA (1) | EA201690673A1 (enExample) |
| IL (1) | IL244620A0 (enExample) |
| MX (1) | MX2016003763A (enExample) |
| SG (1) | SG11201602175VA (enExample) |
| TW (1) | TW201601722A (enExample) |
| UY (1) | UY35748A (enExample) |
| WO (1) | WO2015065628A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| WO2007006307A2 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel salts of fumaric acid monoalkylesters and their pharmaceutical use |
| BRPI0713694A2 (pt) * | 2006-06-12 | 2012-10-30 | Teva Pharma | composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica |
| CN107308162A (zh) * | 2009-06-19 | 2017-11-03 | 泰华制药工业有限公司 | 利用拉喹莫德治疗多发性硬化 |
| EP2736335A4 (en) * | 2011-07-28 | 2015-01-07 | Teva Pharma | TREATMENT OF MULTIPLE SCLEROSIS USING A COMBINATION OF LAQUINIMOD AND GLATIRAMERATE ACETATE |
-
2014
- 2014-09-26 EP EP14857795.0A patent/EP3049075A4/en not_active Withdrawn
- 2014-09-26 TW TW103133660A patent/TW201601722A/zh unknown
- 2014-09-26 BR BR112016006582A patent/BR112016006582A2/pt not_active IP Right Cessation
- 2014-09-26 US US14/498,024 patent/US20150094332A1/en not_active Abandoned
- 2014-09-26 AR ARP140103582A patent/AR097792A1/es unknown
- 2014-09-26 KR KR1020167011039A patent/KR20160085757A/ko not_active Withdrawn
- 2014-09-26 AU AU2014342917A patent/AU2014342917A1/en not_active Abandoned
- 2014-09-26 UY UY0001035748A patent/UY35748A/es not_active Application Discontinuation
- 2014-09-26 CN CN201480053575.8A patent/CN105848653A/zh active Pending
- 2014-09-26 MX MX2016003763A patent/MX2016003763A/es unknown
- 2014-09-26 EA EA201690673A patent/EA201690673A1/ru unknown
- 2014-09-26 JP JP2016516547A patent/JP2016533323A/ja not_active Withdrawn
- 2014-09-26 SG SG11201602175VA patent/SG11201602175VA/en unknown
- 2014-09-26 CA CA2925493A patent/CA2925493A1/en active Pending
- 2014-09-26 WO PCT/US2014/057705 patent/WO2015065628A2/en not_active Ceased
-
2016
- 2016-03-15 IL IL244620A patent/IL244620A0/en unknown
- 2016-05-31 US US15/169,139 patent/US20160271094A1/en not_active Abandoned
-
2017
- 2017-07-06 US US15/643,214 patent/US20170304253A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160085757A (ko) | 2016-07-18 |
| CA2925493A1 (en) | 2015-05-07 |
| AR097792A1 (es) | 2016-04-13 |
| UY35748A (es) | 2015-04-30 |
| US20150094332A1 (en) | 2015-04-02 |
| IL244620A0 (en) | 2016-04-21 |
| US20170304253A1 (en) | 2017-10-26 |
| EP3049075A4 (en) | 2017-05-03 |
| WO2015065628A2 (en) | 2015-05-07 |
| AU2014342917A1 (en) | 2016-04-21 |
| US20160271094A1 (en) | 2016-09-22 |
| EP3049075A2 (en) | 2016-08-03 |
| EA201690673A1 (ru) | 2016-08-31 |
| WO2015065628A3 (en) | 2015-10-29 |
| CN105848653A (zh) | 2016-08-10 |
| BR112016006582A2 (pt) | 2017-08-01 |
| TW201601722A (zh) | 2016-01-16 |
| SG11201602175VA (en) | 2016-04-28 |
| JP2016533323A (ja) | 2016-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491773A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| JO3452B1 (ar) | بنزاميدات أمينو اريل مغاير كمثبطات كيناز | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| PH12015501576A1 (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| MX2015012156A (es) | Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer. | |
| MX2015008187A (es) | Inhibidores de alk deuterados. | |
| EA201591507A1 (ru) | Лечение рассеянного склероза лахинимодом | |
| MX2015000485A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. | |
| PH12014502065A1 (en) | Vesicular formulations | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| SG10201809673RA (en) | Treatment of androgen deprivation therapy associated symptoms | |
| MX2014014816A (es) | Composicion farmaceutica para tratar inflamacion y dolor. | |
| MX2016003763A (es) | Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple. | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process | |
| MX2016001177A (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina. | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| NZ629475A (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
| IN2013MU03428A (enExample) | ||
| HK1223854A1 (zh) | 通过阿仑单抗诱导随後通过拉喹莫德疗法来治疗多发性硬化症 | |
| MX2013002446A (es) | Derivados de tetrahidropirrolopirazina sustituidos. | |
| MX2016008214A (es) | Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida. | |
| IN2013MU01222A (enExample) | ||
| IN2013MU01224A (enExample) |